Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

Main Article Content

Massimo Breccia
Gioia Colafigli
Luisa Quattrocchi
elisabetta abruzzese
giuliana alimena

Keywords

CML, ponatinib, extramedullary localization

Abstract

Ponatinib a third generation tyrosine kinase inhibitor, has been approved for all phases of disease in CML. In advanced phase, has been confirmed with a good efficacy in all type of resistance, including T315I kinase domain mutation. We here report activity of the drug in advanced phase with extramedullary localization.

Downloads

Download data is not yet available.
Abstract 2306 | PDF Downloads 390 HTML Downloads 1740 figure 1 Downloads 0 figure 2 Downloads 0

References

1. O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-12

2. Zhou T, Commodore L, Huang WS, et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011; 77: 1-11

3. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-Positive leukemias. N Engl J Med 2012; 367: 2075-88

4. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783-96

Most read articles by the same author(s)

1 2 > >>